Merck (MRK) EPS (Basic) (2009 - 2026)

Merck (MRK) has reported EPS (Basic) for 18 consecutive years, with -$0.54 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) fell 130.68% year-over-year to -$0.54 in Q2 2026; TTM through Jun 2026 was $1.28, a 80.39% decrease from a year earlier, with the FY2025 full-year figure at $7.3, up 7.87% from the prior year.
• EPS (Basic) was -$0.54 for Q2 2026 at Merck, up from -$1.72 in the prior quarter.
• Over five years, EPS (Basic) peaked at $2.32 in Q3 2025 and troughed at -$2.35 in Q2 2023.
• A 5-year average of $0.98 and a median of $1.38 in 2022 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) tumbled 250.75% in 2023 and surged 405.99% in 2024, its largest moves.
• Over 5 years, EPS (Basic) stood at $1.19 in 2022, then sank by 140.54% to -$0.48 in 2023, then surged by 405.99% to $1.48 in 2024, then decreased by 19.94% to $1.18 in 2025, then plunged by 145.72% to -$0.54 in 2026.
• The last three EPS (Basic) figures came in at -$0.54 (Q2 2026), -$1.72 (Q1 2026), and $1.18 (Q4 2025), per Business Quant data.